Egfr, P53, Idh-1 And Mdm2 Immunohistochemical Analysis In Glioblastoma: Therapeutic And Prognostic Correlation [análise Imunoistoquímica Para Egfr, P53, Idh-1 E Mdm2 Em Glioblastoma: Correlação Terapêutica E Prognóstica]

dc.date2015
dc.date2016-06-03T20:14:43Z
dc.date2016-06-03T20:14:43Z
dc.date.accessioned2018-03-29T01:33:25Z
dc.date.available2018-03-29T01:33:25Z
dc.identifier
dc.identifierArquivos De Neuro-psiquiatria. Associacao Arquivos De Neuro-psiquiatria, v. 73, n. 7, p. 561 - 568, 2015.
dc.identifier0004282X
dc.identifier10.1590/0004-282X20150059
dc.identifierhttp://www.scopus.com/inward/record.url?eid=2-s2.0-84937683910&partnerID=40&md5=e17a645152fa6969d91cb316b347e177
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/238260
dc.identifier2-s2.0-84937683910
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1304921
dc.descriptionWe studied 36 glioblastoma cases at HC-UNICAMP from 2008 to 2012 and classified the immunohistochemical distribution of the wild-type epidermal growth factor receptor (EGFR), mutated forms of p53 protein and isocitrate dehydrogenase-1 (IDH-1) and murine double protein 2 (MDM2). Immunostaining findings were correlated with clinical data and response to treatment (surgery, chemotherapy and radiotherapy). About 97% of the tumors were primary, most of them localized in the frontal lobe. Mean time free of clinical or symptomatic disease and free time of radiological disease were 7.56 and 7.14 months, respectively. We observed a significant positive correlation between expressions of p53 and MDM2, EGFR and MDM2. Clinical, radiological and overall survivals also showed a significant positive correlation. p53 staining and clinical survival showed a significant negative correlation. The current series provides clinical and histopathological data that contribute to knowledge on glioblastoma in Brazilians. © 2015 Associacao Arquivos de Neuro-Psiquiatria. All rights reserved.
dc.description73
dc.description7
dc.description561
dc.description568
dc.descriptionWen, P.Y., Kesari, S., Malignant gliomas in adults (2008) N Engl J Med, 359 (5), pp. 492-507. , http://dx.doi.org/10.1056/NEJMra0708126
dc.descriptionBishop, J.M., Molecular themes in oncogenesis (1991) Cell, 64 (2), pp. 235-248. , http://dx.doi.org/10.1016/0092-8674(91)90636-D
dc.descriptionLouis, D.N., Ohgaki, H., Wiestler, O.D., (2007) WHO Classification of Tumors of the Central Nervous System, pp. 33-49. , 4th Edition. Lyon: International Agency for Research on Cancer
dc.descriptionPelloski, C.E., Ballman, K.V., Furth, A.F., Zhang, L., Lin, E., Sulman, E.P., Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma (2007) J Clin Oncol, 25 (16), pp. 2288-2294. , http://dx.doi.org/10.1200/JCO.2006.08.0705
dc.descriptionCollins, V.P., Mechanisms of disease: Genetic predictors of response to treatment in brain tumors (2007) Nat Clin Pract Oncol, 4 (6), pp. 362-374. , http://dx.doi.org/10.1038/ncponc0820
dc.descriptionFurnari, F.B., Fenton, T., Bachoo, R.M., Mukasa, A., Stommel, J.M., Stegh, A., Malignant astrocytic glioma: Genetics, biology, and paths to treatment (2007) Genes Dev, 21 (21), pp. 2683-2710. , http://dx.doi.org/10.1101/gad.1596707
dc.descriptionSathornsumetee, S., Reardon, D.A., Desjardins, A., Quinn, J.A., Vredenburgh, J.J., Rich, J.N., Molecularly targeted therapy for malignant glioma (2007) Cancer, 110 (1), pp. 13-24. , http://dx.doi.org/10.1002/cncr.22741
dc.descriptionDang, L., White, D.W., Gross, S., Bennett, B.D., Bittinger, M.A., Driggers, E.M., Cancer-associated IDH1 mutations produce 2-hydroxyglutarate (2009) Nature, 462 (7274), pp. 739-744. , http://dx.doi.org/10.1038/nature08617
dc.descriptionSmeitink, J., Metabolism, gliomas, and IDH1 (2010) N Engl J Med, 362 (12), pp. 1144-1145. , http://dx.doi.org/10.1056/NEJMcibr0912922
dc.descriptionYan, H., Parsons, D.W., Jin, G., McLendon, R., Rasheed, B.A., Yuan, W., IDH1 and IDH2 mutations in gliomas (2009) N Engl J Med, 360 (8), pp. 765-773. , http://dx.doi.org/10.1056/NEJMoa0808710
dc.descriptionJuratli, T.A., Kirsch, M., Geiger, K., Klink, B., Leipnitz, E., Pinzer, T., The prognostic value of IDH mutations and MGMT promoter status in secpmdary high-grade gliomas (2012) J Neurooncol, 110 (3), pp. 325-333. , http://dx.doi.org/10.1007/s11060-012-0977-2
dc.descriptionComb, S., Rieken, S., Wick, W., Abdollahi, A., Deimling, A., Debus, J., Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: One step forward, and one step back? (2011) Radiat Oncol, 6 (1), p. 115. , http://dx.doi.org/10.1186/1748-717X-6-115
dc.descriptionOhno, M., Narita, Y., Miyakita, Y., Matsushita, Y., Yoshida, A., Fukushima, S., Secondary glioblastomas with IDH1/2 mutations have longer glioma history from preceding lower-grade gliomas (2013) Brain Tumor Pathol, 30 (4), pp. 224-232. , http://dx.doi.org/10.1007/s10014-013-0140-6
dc.descriptionGiordana, M.T., Duó, D., Gasverde, S., Trevisan, E., Boghi, A., Morra, I., MDM2 overexpression is associated with short survival in adults with medulloblastoma (2002) Neuro Oncol, 4 (2), pp. 115-122. , http://dx.doi.org/10.1093/neuonc/4.2.115
dc.descriptionKorkolopoulou, P., Christodoulou, P., Kouzelis, K., Hadjiyannakis, M., Priftis, A., Stamoulis, G., MDM2 and p53 expression in gliomas: A multivariate survival analysis including proliferation markers and epidermal growth factor receptor (1997) Br J Cancer, 75 (9), pp. 1269-1278. , http://dx.doi.org/10.1038/bjc.1997.216
dc.descriptionBrandsma, D., Stalpers, L., Taal, W., Sminia, P., Van Den Bent, M.J., Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas (2008) Lancet Oncol, 9 (5), pp. 453-461. , http://dx.doi.org/10.1016/S1470-2045(08)70125-6
dc.descriptionBrem, S.S., Bierman, P.J., Black, P.H., Brem, H., Chamberlain, M.C., Chiocca, E.A., Central nervous system cancers (2008) J Natl Compr Canc Netw, 6 (5), pp. 456-504
dc.descriptionBarajas, R.F., Jr., Phillips, J.J., Parvataneni, R., Molinaro, A., Essock-Burnes, E., Bourne, G., Regional variation in histopathologic features of tumor specimens from treatment-naive glioblastoma correlates with anatomic and physiologic MR imaging (2012) Neuro-Oncol, 14 (7), pp. 942-954. , http://dx.doi.org/10.1093/neuonc/nos128
dc.descriptionJain, R.K., Di Tomaso, E., Duda, D.G., Loeffler, J.S., Sorensen, A.G., Batchelor, T.T., Angiogenesis in brain tumours (2007) Nat Rev Neurosci, 8 (8), pp. 610-622. , http://dx.doi.org/10.1038/nrn2175
dc.descriptionGuo, P., Hu, B., Gu, W., Xu, L., Wang, D., Huang, H.J., Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment (2003) Am J Pathol, 162 (4), pp. 1083-1093. , http://dx.doi.org/10.1016/S0002-9440(10)63905-3
dc.description
dc.description
dc.languageen
dc.publisherAssociacao Arquivos de Neuro-Psiquiatria
dc.relationArquivos de Neuro-Psiquiatria
dc.rightsfechado
dc.sourceScopus
dc.titleEgfr, P53, Idh-1 And Mdm2 Immunohistochemical Analysis In Glioblastoma: Therapeutic And Prognostic Correlation [análise Imunoistoquímica Para Egfr, P53, Idh-1 E Mdm2 Em Glioblastoma: Correlação Terapêutica E Prognóstica]
dc.typeArtículos de revistas
dc.typeErrata


Este ítem pertenece a la siguiente institución